

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :	A1	(11) International Publication Number: WO 94/20114
A61K 31/70, C07H 1/00, 15/24		(43) International Publication Date: 15 September 1994 (15.09.94)

(21) International Application Number: PCT/US94/02619	(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(22) International Filing Date: 11 March 1994 (11.03.94)	
(30) Priority Data: 08/031,173 12 March 1993 (12.03.93) US	Published <i>With international search report.</i>
(71) Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US).	
(72) Inventors: PRIEBE, Waldemar; 4239 Emory, Houston, TX 77005 (US). SKIBICKI, Piotr; ul. Waszyngtona, PL-04-015 Warsaw (PL). PEREZ-SOLER, Roman; 2904 Rice Boulevard, Houston, TX 77005 (US).	
(74) Agent: WILSON, Mark, B.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).	

(54) Title: ANTHRACYCLINES WITH UNUSUALLY HIGH ACTIVITY AGAINST CELLS RESISTANT TO DOXORUBICIN AND ITS ANALOGS



(57) Abstract

The present disclosure details novel modified anthracyclines, the synthesis thereof, and their use in treating patients with tumors. Preferred aspects of the disclosure involve modified anthracyclines which have an O-substituted aromatic ring on their sugar moiety. Other preferred aspects of the disclosure involve synthesis steps wherein a hydroxyl group on a sugar moiety to be added is blocked with a halo-substituted alkyl group during the process of adding it to an anthracycline ring compound.

1925
#13

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

DESCRIPTION

ANTHACYCLINES WITH UNUSUALLY HIGH ACTIVITY AGAINST
CELLS RESISTANT TO DOXORUBICIN
AND ITS ANALOGS

5

BACKGROUND OF THE INVENTION

10 1. Field of the Invention

This application relates generally to the treatment of cancer. Specifically, the invention relates to novel compounds useful for chemotherapy, methods of synthesis of these compounds, and methods of treatment employing these compounds. The novel compounds described are analogs of the doxorubicin which is known to have anti-tumor effects.

20 2. Description of the Related Art

Resistance of tumor cells to the killing effects of chemotherapy is one of the central problems in the management of cancer. It is now apparent that at diagnosis many human tumors already contain cancer cells that are resistant to standard chemotherapeutic agents. Spontaneous mutation toward drug resistance is estimated to occur in one of every 10⁶ to 10⁷ cancer cells; this mutation rate appears to be independent of any selective pressure from drug therapy, although radiation therapy and chemotherapy may give rise to additional mutations and contribute to tumor progression within cancer cell populations (Goldie et al., *Cancer Treat. Rep.*, 63:1727, 1979; Goldie et al., *Cancer Res.*, 44:3643, 1984; and Nowell, *Cancer Res.*, 46:2203, 1986). The cancer cell burden at diagnosis is therefore of paramount importance because even tumors as small as 1 cm (10⁹ cells) could

-2-

contain as many as 100 to 1,000 drug-resistant cells prior to the start of therapy.

Selective killing of only the tumor cells sensitive
5 to the drugs leads to an overgrowth of tumor cells that are resistant to the chemotherapy. Mechanisms of drug resistance include decreased drug accumulation (particularly in multidrug resistance), accelerated catabolism of the drug and other alterations of drug
10 metabolism, and an increase in the ability of the cell to repair drug-induced damage (Curt et al., *Cancer Treat. Rep.*, 68:87, 1984; and Kolate, *Science*, 231:220, 1986). The cells that overgrow the tumor population not only are resistant to the agents used but also tend to be
15 resistant to other drugs, many of which have dissimilar mechanisms of action. This phenomenon, called pleiotropic drug resistance or multidrug resistance (MDR), may account for much of the drug resistance that occurs in previously treated cancer patients.

20

Gene amplification (i.e., the production of extra copies of genes within a cell) is one of the mechanisms that can lead to drug resistance. Gene amplification is involved in the phenomenon of multidrug resistance.
25 Multidrug resistance appears to be linked to over-expression of a cell membrane glycoprotein, termed P-glycoprotein, on the surface of cancer cells (Bell et al., *J. Clin. Oncol.*, 3:311, 1985; and Bertino, *J. Clin. Oncol.*, 3:293, 1985). The action of this glycoprotein is
30 unknown, but its over-expression is associated with decreased accumulation of multiple chemotherapeutic drugs within the resistant cells. A multidrug-resistance gene that encodes the P-glycoprotein has been isolated and sequenced, and when it is transferred, this gene confers drug resistance on previously drug-sensitive cells (Gros et al., *Nature*, 323:728, 1986). The multidrug-resistance gene termed *mdrl* is expressed in several normal tissues,

-3-

and its expression is increased in some human tumors (Fojo et al., *P.N.A.S.*, 84:265, 1987). Various human tumors are now being analyzed to determine whether they express this gene. Because many heavily treated patients
5 who are in relapse harbor tumors that do not show over-expression of the *mdrl* gene, it appears that other mechanisms are probably also involved in causing resistance to chemotherapy.

10 The commonly used chemotherapeutic agents are classified by their mode of action, origin, or structure, although some drugs do not fit clearly into any single group. The categories include alkylating agents, antimetabolites, antibiotics, alkaloids, and
15 miscellaneous agents (including hormones); agents in the different categories have different sites of action.


Antibiotics are biologic products of bacteria or fungi. They do not share a single mechanism of action.
20 The anthracyclines daunorubicin and doxorubicin (DOX) are some of the more commonly used chemotherapeutic antibiotics. The anthracyclines achieve their cytotoxic effect by several mechanisms, including intercalation between DNA strands, thereby interfering with DNA and RNA
25 synthesis; production of free radicals that react with and damage intracellular proteins and nucleic acids; chelation of divalent cations; and reaction with cell membranes. The wide range of potential sites of action may account for the broad efficacy as well as the
30 toxicity of the anthracyclines (Young et al., *N. Engl. J. Med.*, 312:692, 1985).

The anthracycline antibiotics are produced by the fungus *Streptomyces peucetius* var. *caesius*. Although
35 they differ only slightly in chemical structure, daunorubicin has been used primarily in the acute leukemias, whereas doxorubicin displays broader activity

-4-

against human neoplasms, including a variety of solid tumors. The clinical value of both agents is limited by an unusual cardiomyopathy, the occurrence of which is related to the total dose of the drug; it is often irreversible. In a search for agents with high antitumor activity but reduced cardiac toxicity, anthracycline derivatives and related compounds have been prepared. Several of these have shown promise in the early stages of clinical study, including epirubicin and the synthetic compound mitoxantrone, which is an amino anthracenedione.

The anthracycline antibiotics have tetracycline ring structures with an unusual sugar, daunosamine, attached by glycosidic linkage. Cytotoxic agents of this class all have quinone and hydroquinone moieties on adjacent rings that permit them to function as electron-accepting and donating agents. Although there are marked differences in the clinical use of daunorubicin and doxorubicin, their chemical structures differ only by a single hydroxyl group on C14. The chemical structures of daunorubicin and doxorubicin are as follows:



35 Daunorubicin: R = H
 Doxorubicin: R = OH

-5-

Unfortunately, concomitant with its antitumor activity, DOX can produce adverse systemic effects, including acute myelosuppression, cumulative cardiotoxicity, and gastrointestinal toxicity (Israel et al., *Cancer Treat. Rec.*, 14:163, 1987). At the cellular level, in both cultured mammalian cells and primary tumor cells, DOX can select for multiple mechanisms of drug resistance that decrease its chemotherapeutic efficacy. These mechanisms include Pgp-mediated MDR, characterized by the energy-dependent transport of drugs from the cell (Bradley et al., *Biochem. Biophys. Acta.*, 948:87, 1988), and resistance conferred by decreased topoisomerase II activity, resulting in the decreased anthracycline-induced DNA strand scission (Danks et al., *Cancer Res.*, 47:1297, 1987; Pommier et al., *Cancer Res.*, 46:3075, 1986; Moscow et al., *J. Natl. Cancer Inst.*, 80:14, 1988).

Among the potential avenues of circumvention of systemic toxicity and cellular drug resistance of the natural anthracyclines is the development of semisynthetic anthracycline analogues which demonstrate greater tumor-specific toxicity and less susceptibility to various forms of resistance. One such analogue, AD 198, exhibits a variety of mechanistic differences compared with anthracycline, including weaker binding to purified DNA, preferential inhibition of RNA versus DNA synthesis, irreversible G₂/M blockade, pronounced membrane lytic activity, and a lack of inhibition of purified mammalian topoisomerase II despite significant levels of protein-associated DNA strand breaks in alkaline elution assays (Israel et al., 1987; Traganos et al., *Cancer Res.*, 45:6273, 1985; Bodley et al., *Cancer Res.*, 49:5969; and Israel et al., *Cancer Chemother. Pharmacol.*, 25:177, 1989). When compared with anthracycline, AD 198 demonstrates enhanced cytotoxicity against cultured murine and human tumor cells and the ability to circumvent MDR in P388 and L1210 leukemic cells and B16-

-6-

BL6 melanoma cells, and both MDR and resistance due to altered topoisomerase II activity in variant CCRF-CEM leukemic cells (Ganapath, et al., *Br. J. Cancer*, 60:819, 1989; Sweatman et al., *J. Cell. Pharmacol.*, 1:95-102).
5 Unfortunately, despite the high degree of toxicity seen in vitro, AD 198 exhibits limited efficacy against transplanted MDR L1210 cells in vivo. This observation suggests that resistance to AD 198 may be conferred either systemically through enhanced drug metabolism or
10 pharmacologic sanctuary of the neoplasia or through cellular resistance (Ganapathi et al.).

AD 198 is an anthracycline analogue designed to circumvent MDR and thereby enhance chemotherapeutic efficacy against drug resistant neoplastic cells.
15 Circumvention of MDR by AD 198 appears to be due, at least in part, to the inability of P-gp to transport AD 198 from the cell (Sweatman et al.). Cellular resistance to AD 198 can emerge rapidly within murine macrophagelike
20 J774.2 cells and with characteristics that were similar to those of MDR. However, AD 198^R cells differ from MDR cells in the persistence of high levels of intracellular AD 198 similar to that of drug-sensitive cells.
Resistance to AD 198 could limit the successful
25 utilization of this and other highly hydrophobic anthracycline analogues in the treatment of MDR tumor cells. In addition, it has been shown that MDR J774.2 selected with vinblastine were cross-resistant to AD 198. This finding was in contrast to previous studies showing
30 the ability of AD 198 to circumvent MDR in lymphocytic and melanoma cell lines selected with either anthracycline or vinblastine (Ganapathi et al.; Sweatman et al.), suggesting that cell type may have a significant effect upon the MDR phenotype which emerges in response
35 to challenge with a particular drug.

-7-

A further example of cell type effecting the drug resistance phenotype with regard to a particular drug is seen in the various particular AD 198 resistant cells. Two types of AD 198-resistant cells are the AD 198^R cells,
5 which are created by selecting AD 198 resistant cells from the normally AD 198 susceptible J774.2 cells, and the A300 cells, which are created by selecting cells with even greater resistance to AD 198 than the normally
resistant A100 cells (Lothstein et al. *Cancer R.*,
10 52:3409 (1992). Although both AD 198^R cells and A300 cells are resistant to AD 198, the basis of the resistance appears to be different between the cell types (Lothstein).

15 The development of drug resistance is one of the major obstacles in the management of cancer. There are various types of drug resistance, for example, classic MDR as opposed to AD 198 resistance. Furthermore, different cell lines can establish resistance to the same
20 drug in different ways, as seen in the case of the differences in AD 198 resistance in AD 198^R cells as opposed to A300 cells. One of the traditional ways to attempt to circumvent this problem of drug resistance has been combination chemotherapy.

25 Combination drug therapy is the basis for most chemotherapy employed to treat breast, lung, and ovarian cancers as well as Hodgkin's disease, non-Hodgkin's lymphomas, acute leukemias, and carcinoma of the testes.

30 Combination chemotherapy uses the differing mechanisms of action and cytotoxic potentials of multiple drugs. Although all chemotherapeutic drugs are most effective on cells that are active in DNA synthesis, many
35 agents--particularly the alkylating agents--can kill cells that are not cycling. Such agents are termed non-cell proliferation-dependent agents can shrink tumor mass

-8-

by reducing cell numbers; the surviving cells will then move into the cycling compartment, where they are more susceptible to cell proliferation-dependent drugs. The combined use of agents less dependent on the cell cycle
5 followed by those dependent on cell proliferation is effective in enhancing tumor cell death. Each cycle of treatment kills a fixed fraction of cells, so repetitive cycles are required for cure. For example, a drug combination that kills 99.9 percent of cancer cells per
10 treatment cycle would have to be repeated at least six times to eliminate an average tumor burden (if tumor cells did not regrow between cycles).

Although combination chemotherapy has been
15 successful in many cases, the need still exists for new anti-cancer drugs. These new drugs could be such that they are useful in conjunction with standard combination chemotherapy requires, these new drugs could attack drug resistant tumors by having the ability to kill cells of
20 multiple resistance phenotypes. For example, a drug that has the ability to kill cells with both MDR and AD 198 resistance could eliminate two populations of resistant cells from a tumor.

25 A drug that exhibits the ability to overcome multiple drug resistances could be employed as a chemotherapeutic agent either alone or in combination with other drugs. The potential advantages of using such a drug in combination with chemotherapy would be the need
30 to employ fewer toxic compounds in the combination, cost savings, and a synergistic effect leading to a treatment regime involving fewer treatments.

-9-

SUMMARY OF THE INVENTION

This invention involves novel compounds that have utility as anti-tumor and/or chemotherapeutic drugs,
5 methods of synthesizing these compounds, and methods of using these compounds to treat patients with cancer. It has been discovered that anthracycline derivatives that have aromatic rings attached to their sugar moiety have a surprisingly strong ability to kill tumor cells.
10 Furthermore, these compounds are effective against cells with any of a variety of different forms of drug resistance, for example: MDR, AD 198 resistance, and vinblastine resistance. In light of this surprisingly broad cytotoxic ability, the compounds of the present
15 invention exhibit potential for use as chemotherapeutic drugs. The aromatic substitution in the more specific embodiments of these compounds is made using an oxygen linkage from C-3 of the sugar moiety. Doxorubicin and doxorubicin analogs have an amine group attached to C-3,
20 and this is replaced in the compounds of this invention.

The anthracycline derivatives that have these modifications have been shown to have the ability to kill tumor cells which are resistant to known chemotherapeutic agents, including doxorubicin and modified anthracycline derivatives. For example, two of these compounds which are O-benzylated at the 3' carbon of the sugar moiety, WP 546 and WP 549, have very high cytotoxicity against tumor cells that are resistant to doxorubicin, AD 198, and
25 vinblastine. Specifically, these compounds have been shown to kill KB V1 cells and J774.2 cells, both of which exhibit classic MDR to doxorubicin. Further, these compounds have demonstrated cytotoxicity against AD 198 resistant cells such as J7/A300 cells and P388 cells.
30 Finally, these compounds have been shown to have cytotoxic effects against J7/40V cells, which are resistant to vinblastine. This is a surprising result in
35

-10-

that resistance to these three compounds occurs by differing mechanisms. Therefore, WP 546 and WP 549 have the ability to overcome all of these mechanisms of drug resistance.

5

Because of they exhibit the ability to kill many types of resistant tumor cells, WP 546, WP 549, and other anthracycline derivatives that have aromatic rings substituted on their sugar moieties should be of great 10 utility as chemotherapeutic compounds. Chemotherapeutic regimes usually involve a combination of agents. This combination therapy is necessitated by the presence of populations of cells within a tumor that may be resistant to one or another of the individual drugs used.

15 Furthermore, even a combination therapy may not be available for some forms of tumors. Given that the compounds claimed in this application exhibit a broad cytotoxic ability against a variety of cells with a variety of differing drug resistances, the need for 20 combination therapy may be reduced by the present compounds. For example, it may be that only one chemotherapeutic agent comprising one of these compounds is required to treat a tumor. Likewise, it may be that the need for combinations of agents still exists, but 25 that the number of toxic compounds introduced into a patient may be reduced. For example, instead of a combination therapy in which doxorubicin, AD 198, vinblastine, and other agents are required to kill all of a particular type of tumor, WP 549 can replace the 30 doxorubicin, AD 198, and vinblastine. Obviously, there are huge potential benefits to reducing the number of chemotherapeutic agents given to a patient, as each agent is a toxin and potentially has its own specific side-effects and cross reactions with other compounds.

35

The Inventors have also found that the substitution of an alkyl-halo-substituted group, particularly a fluoro-


-11-

methyl group, for the C-6 methyl group of the sugar moiety of these anthracycline analogs can have the surprising effect of stabilizing the molecule. This stabilization could result in compounds that exhibit this
 5 fluoro-methyl substitution being more active than those which do not. The Inventors' hypothesis is that this alkyl-halo substitution will be of benefit in many anthracycline derivatives, not only those that have aromatic ring substitutions on their sugar moieties.

10

The general structural formula of these novel compounds of the present invention is:

15



20

25 In these compounds, R¹ can be almost any form of organic group such as a hydrogen, a hydroxyl group, an alkyl group, an arylalkyl group, an alkyl in ester linkage group, or the like. Preferred embodiments of the invention will have a hydroxyl group at R¹. In some
 30 preferred embodiments of the invention, the R¹ hydroxyl group will be acylated. In the most preferred embodiments of these novel compounds, the R¹ hydroxyl group will be either a free hydroxyl group or O-valerate. WP 546 and WP 549 are examples of these most preferred
 35 embodiments.

-12-

R² is the 0-substituted moiety on the sugar portion of the anthracycline compound. R² is typically a CH₂-Ar group, where Ar is further defined as being an aryl group such as benzene, toluene, xylene, mesitylene, cumene, 5 cymene, styrene, naphthalene, etc. In preferred embodiments of the claimed compounds, the Ar group at R² will be a phenyl ring. In other words, the sugar molecule will be O-benzylated at C-3. In the fluoro-methylated forms of the compounds, R² need not necessarily 10 be a CH₂-Ar group and could potentially be a hydrogen, a hydroxyl group, an alkyl group, an arylalkyl group, or an alkyl in ester linkage group.



Those of skill in the art will appreciate that many 15 potential modifications could be made at various points on the claimed compounds, with minimal effort and using standard organic synthesis techniques. Potential sites for such modification can be almost anywhere on the molecule, for example, at those denoted R¹, R³, R⁴, and R⁵ 20 in the above structure. Potential modifications could be having the various sites substituted with, for example, a hydrogen, a hydroxyl group, an alkyl group, an arylalkyl group, or an alkyl in ester linkage group. However, in most of the compounds, R³ is a hydrogen or OCH₃ group, 25 while R⁴ and R⁵ are either hydrogen or hydroxyl groups.

The Inventors have found that a 6-fluoro group at X on the sugar moiety can have a stabilizing effect on anthracycline structures. A 6-fluoro-methyl group has 30 been used for this purpose and it is anticipated that many alkyl-halo-substituted groups will have such utility. Therefore, X is either an alkyl or alkyl-halo-substituted group. In preferred embodiments on the invention, the X portion of the compound will be either a methyl group or 35 a fluoro-methyl group. In a preferred embodiment, X is a methyl group. In another preferred embodiment, X is a fluoromethyl group while R² is a hydrogen. In other

-13-


preferred embodiments of the present invention, X is a methyl group and Ar is a phenyl group.

The most preferred embodiments of the present invention are WP 546 and WP 549. WP 546 (7-O-(3-O-benzyl-2,6-dideoxy- α -L-lyxo-hexopyranosyl)adriamycinone), has a free hydroxyl group at R¹, a benzyl group at R², an OCH₃ group at R³, a free hydroxyl group at R⁴, a hydrogen at R⁵, and a methyl group at X. WP 549 (7-O-(3-O-benzyl-2,6-dideoxy- α -L-lyxo-hexopyranosyl)-14-O-valeroyl adriamycinone) is the same as WP 546, except that it has an O-valerate group at R¹. The structures of WP 546 and WP 549 are as follows:



-14-

Of course, those of skill in the art understand that minor modifications in the above described embodiments of the present invention are possible. Such modified compounds are also covered by this application. For example, it would be possible to modify the basic structure of the compounds at other sites, such as Z and Y on the structure below:



In this modified structure, the Z site could be CHF, CF₂, O, N or S, while the Y site could be O; H,H; or H,OH. Any of these modifications could be readily made by those of skill in the art.

25

Other aspects of the present invention involve the synthesis of the novel compounds described above. During the elucidation of the synthesis processes, the inventors found that, surprisingly, the standard organic chemistry step of blocking the hydroxy group at C-4 on the sugar with an acetyl group did not work because the blocking group could not later be removed. The inventors hypothesized that this effect was due to the presence of the benzyl group on the sugar. Therefore, the inventors attempted blocking of the hydroxyl group at C-4 with trifluoroacetate. Trifluoroacetate is typically considered to be too weak of a blocker to have utility in

of trifluoroacetate
ty in the present
s of the synthesis
ne sugar will be

isclosed compounds
546, and WP 549.
the sugar moiety of
Figure 1. Further,
in Figure 2, while
both descriptions of
ns of these compounds
d Description of the
e application.

e required for some
1 can be easily
sugars can be
L-sugars containing 6-
proaches may be used
an be derived to form
etc.) and subsequent
ie can occur; or 2)
ectly reacted with
). As an example of
 β -D- α -L-glucopyranoside
-6-fluoro- α -L-
details are given in
Such 6-fluoro-
rmed into 3'-OH and
nthetic procedures.

e art will appreciate
thesis of the above
ents of the invention
e present

-16-

application. For example, 3-O-Benzyl-2,6-dideoxyhexopyranoses or hexopyranosides could be used as the sugar moiety, for direct coupling with a proper aglycon. Should these different sugar moieties be used, those of skill in the art will understand that different coupling reagents will be necessary, and these are standard in the art. The preferred coupling reagent for use with hexopyranoses and hexopyranosides is trimethylsilyltriflate.

10

Other aspects of the claimed invention include methods of treating a patient with cancer. These methods involve administering to a patient a therapeutically effective amount of any of the above described novel compounds. It is anticipated that these compounds will have great utility as chemotherapeutic agents. This is especially true in light of the fact that the above described agents exhibit such broad cytotoxic effects.

20

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1: The synthesis of the sugar portions of WP 549 and WP 546.

25 **Figure 2:** The synthesis of WP 549.

Figure 3: The synthesis of WP 546.

KEY TO FIGURES 1-3:

1	=	L-fucal
30	2	= 3,4-di-O-benzyl-L-fucal
3	=	3-O-benzyl-L-fucal
4	=	4-O-benzyl-L-fucal
5	=	3-O-benzyl-4-O-trifluoroacetyl-L-fucal
6	=	daunomycinone
35	7	= 14-bromodaunomycinone
8	=	14-O-valeroyldaunomycinone

-17-

9 = 7-O-(3-O-benzyl-2,6-dideoxy-4-O-trifluoroacetyl- α -L-lyxo-hexopyranosyl)-14-O-valeroyladriamycinone
10 = 14-O(t-butyl-dimethylsilyl)-adriamycinone
5 11 = 7-O-(3-O-benzyl-2,6-dideoxy-4-O-trifluoroacetyl- α -L-lyxo-hexopyranosyl)-14-O-(t-butyldimethylsilyl)adriamycinone
12 = 7-O-(3-O-benzyl-2,6-dideoxy- α -L-lyxo-hexopyranosyl)-14-O-(t-butyl-dimethylsilyl)adriamycinone
10 WP 546 = 7-O-(3-O-benzyl-2,6-dideoxy- α -L-lyxo-hexopyranosyl)adriamycinone
WP 549 = 7-O-(3-O-benzyl-2,6-dideoxy- α -L-lyxo-hexopyranosyl)-14-O-valeroyladriamycinone
15

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The following examples are included only to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

In a series of studies demonstrating the surprising and unexpected antitumor activities of the novel compounds of the claimed invention, anthracyclines with the 3'-amino group replaced with O-benzyl substituent and either having the 14 hydroxy group free or acylated were prepared using a multi-step synthesis. All congeners

-18-

were tested for cytotoxic activity *in vitro* against doxorubicin (DOX) sensitive and multidrug resistant (MDR) cell lines. The cytotoxic properties of 3'-O-benzyl-doxorubicin were surprisingly similar in DOX-sensitive and DOX resistant cell lines. The observed activity against the resistant cells was unexpectedly high. The resistant indices were often below the value of 1, indicating higher activity of the inventive compounds against cells resistant to AD 198 or vinblastine than those cells that were not resistant to those drugs (see Tables 1 and 2). The synthesized compounds were shown to have cytotoxic activity against J774.2 cells (DOX resistant), J7/A300 cells, (resistant to DOX and AD 198). Therefore, the novel anthracycline derivatives of the present invention have the ability to kill an unusually broad variety of tumor cells and overcome a variety of drug resistances. As a result, it is anticipated that the novel anthracycline derivatives of the present invention will have great utility in the treatment of tumors.

EXAMPLE I

Preparation of Anthracycline Derivatives:

The 3'-O-benzyl-doxorubicin (WP 546) and its 14-O-valerate ester (WP 549) were prepared from 3-O-benzyl-L-fucal in electrophilic addition reaction using triphenylphosphine hydrobromide (TPHB) and 14-O-acylated aglycone. The synthetic processes are diagramed in Figures 1-3, and the numbers in parenthesis after chemical names in the text are keyed in the Figures.

Synthesis of Sugar Portion of Compound

The sugar position of both WP 546 and WP 549 was synthesized as follows. This synthesis is detailed in Figure 1.

-19-

3-O-benzyl-4-O-trifluoroacetyl-L-fucal (5) for use in the synthesis of WP 546 and WP 549 was prepared by the following method; Figure 1. L-Fucal (1) (5.36 g, 0.041 mol) in DMF (48 ml) was added to the solution of sodium hydride (60% dispersion in mineral oil, 1.81 g, 0.045 mol) in DMF (125 ml) at 0°C. Then benzyl chloride (5.3 ml, 0.046 mol) was added. The reaction mixture was stirred for 2 hours. Then methanol (53 ml) and water (300 ml) were added and products were extracted with diethyl ether. Organic extract was dried over anhydrous sodium sulfate. Crude reaction mixture was chromatographed on the silica gel column (200 g) in hexane/diethyl ether/methanol 80/20/2 solvent system to give: 1.05 g of 3,4-di-O-benzyl-L-fucal 2 (8.3%), 2.89 g of 3-O-benzyl-L-fucal (3) (32%) and 3.40 g of 4-O-benzyl-L-fucal (4) (37.6%).

Next, 3-O-Benzyl-4-O-trifluoroacetyl-L-fucal (5) was synthesized. 3-O-benzyl-L-fucal (3) (1.09 g, 4.94 mmol) was dissolved in dichloromethane (44 ml) under nitrogen and triethylamine (13.3 ml) was added. The reaction mixture was cooled down (ice bath) and trifluoroacetic anhydride (6.8 ml, 48.14 mmol) was added. After 2 hours there was no substrate in the reaction mixture. Solvent was evaporated in vacuo and the reaction mixture was dried under high vacuum. Crude reaction mixture was chromatographed on the silica gen column (60 g) in hexane/ethyl acetate 95/5 solvent system to give 997.2 mg (63.8%) of 3-O-benzyl-4-O-trifluoroacetyl-L-fucal (5) which could then be used in the following synthesis reactions.

Synthesis of WP 549

35 7-O-(3-O-benzyl-2,6-dideoxy- α -L-lyxo-hexopyranosyl)-14-O-valeroyladriamycinone (WP 549), was synthesized according to the scheme detailed in Figure 2.

-20-

Briefly the synthesis was as follows:

14-Bromodaunomycinone (7) was first prepared.
Daunomycinone (6) (360.2 mg, 0.90 mmol) was dissolved in
5 anhydrous chloroform (45 ml). Then solution A (3.1 g of
Br₂ in 30 ml of CHCl₃). (9.6 ml) was added. The reaction
mixture was stirred at the room temperature for 4 hours.
Then the reaction mixture was diluted with hexane and the
precipitate was filtered off. This precipitate was
10 dissolved in chloroform and the resulting solution was
concentrated in vacuo. 14-Bromodaunomycinone (7) (353.1
mg, 81.1%) was filtered off and washed with hexane.

14-O-Valeroyl daunomycinone (8) was then synthesized
15 as follows. 14-Bromodaunomycinone (7) (206.6 mg, 0.43
mmol) was dissolved in dry acetone (80 ml) and cesium
valerate (200 mg, 0.85 mmol) was added. After 15 min.
reaction mixture was diluted with dichloromethane, washed
with water and dried over anhydrous sodium sulfate. 14-O-
20 Valeroyl daunomycinone (8) (180.4 mg, 83.6%) was
precipitated from dichloromethane/hexane solvent system
and separated by centrifugation.

14-O-substituted anthracyclines such as the 14-O--
25 valeroyl daunomycinone prepared above have been previously
prepared by nucleophilic substitution of 14-bromo
derivatives using sodium or potassium salts of carboxylic
acids. The Inventors have found that the synthesis can
be performed with higher yield and higher purity when
30 cesium salts were used. As an example, cesium valerate
was synthesized and successfully used towards preparation
of the 14-O-valeroyl derivative (9). To prepare cesium
valerate, a solution of cesium carbonate (20 g) in
anhydrous methyl alcohol (480 ml) was added to a solution
35 of valeric acid (20 ml) in methyl alcohol (120 ml).
After addition, the reaction mixture was stirred for 30
min. Then methyl alcohol was removed in vacuo and

-21-

crystalline residue was washed with diethyl ether (10 times) and dried under high vacuum to give 13.6 g (95.3 %) of cesium valerate.

5 7-O-(3-O-Benzyl-2,6-dideoxy-4-O-trifluoroacetyl- α -L-lyxo-hexopyranosyl)-14-O-valeroyladriamycinone (9) was prepared as follows. 14-O-Valeroyldaunomycinone (8) (120.2 mg, 0.24 mmol) was dissolved in dry dichloromethane (23 ml) and then TPHB (triphenylphosphine hydrobromide) (306.7 mg, 0.89 mmol, 0.76 eq), molecular sieves (3Å, 600 mesh, 210 mg) and 3-O-benzyl-4-O-trifluoroacetyl-L-fucal 5 (369.0 mg, 1.17 mmol, 4.9 eq.) were added. After 24 hours reaction was completed. The reaction mixture was diluted with dichloromethane and washed with 20% aq. solution of sodium bicarbonate, water and dried over anhydrous sodium sulfate. Crude reaction mixture was chromatographed on the silicagel (26 g, flash) column in the toluene/acetone 98/2 solvent system to give 132.1 mg of product 9. Then the polarity of the eluent was increased (toluene/acetone 9/1) and compound 549 (product of hydrolysis of trifluoroacetyl group on the silicagel, 45.8 mg) was collected. Compound 9 (111.4 mg) was precipitated from diethyl ether and WP 549 (22.2 mg) from tetrahydrofuran/diethyl ether/hexane solvent system. Total yield (products 9 and WP 549) was 69.8%.

The synthesis of 7-O-(3-O-benzyl-2,6-dideoxy- α -L-lyxohexopyranosyl)-14-O-valeroyladriamycinone (WP 549) was then completed as follows. Compound 9 (98.5 mg, 0.12 mmol) was dissolved in tetrahydrofuran (12.8 ml) and water (6.5 ml). Then saturated aqueous solution of sodium bicarbonate (0.24 ml) were added and after four hours the reaction mixture was diluted with dichloromethane, washed with water and dried over sodium sulfate. Crude reaction mixture was chromatographed on the silica gel column (6 g) in toluene/acetone solvent system to give 76 mg of fraction containing product 549.

-22-

WP 549 was further purified by precipitation from tetrahydrofuran/diethyl ether/hexane. Yield after precipitation (69.7 mg) was 80.1%.

5 Synthesis of WP 546

7-O-(3-O-benzyl-2,6-dideoxy- α -L-lyxo-hexopyranosyl)-adriamycinone (WP 546) was synthesized according to the scheme detailed in Figure 2.

10

Briefly, the synthesis was as follows:

7-O-(3-O-Benzyl-2,6-dideoxy-4-O-trifluoroacetyl- α -L-lyxo-hexopyranosyl)-14-O-(t-butyldimethylsilyl)-adriamycinone (11) was first prepared. 3-O-Benzyl-4-O-trifluoroacetyl-L-fucal (5) (200 mg, 0.63 mmol) was dissolved in benzene (12 ml) and dry HCl was bubbled for 15 min. The benzene was evaporated and the reaction mixture A was evaporated with benzene. A mixture of 14-O-(t-butyl-dimethylsilyl)-adriamycinone (10) (131.7 mg, 0.25 mmol), mercury (II) oxide (565 mg, 2.6 mmol), mercury (II) bromide (130.6mg, 0.36 mmol) and molecular sieves (3Å, 600 mesh, 580 mg) in dichloromethane (11 ml) was stirred for 40 min. before the reaction mixture A (in 8 ml of dichloromethane) was added. After 1 hour, the reaction mixture was diluted with dichloromethane, filtered and washed with 10% aq. solution of potassium iodide, water, and then dried over anhydrous sodium sulfate. After evaporation of solvents, crude product 11 (337, 15 mg) was used in the next step without further purification.

7-O-(3-O-Benzyl-2,6-dideoxy- α -L-lyxo-hexopyranosyl)-14-O-(t-butyl-dimethylsilyl)adriamycinone (12) was then synthesized as follows. Crude product 11 (300 mg) was dissolved in the 1:1 mixture of tetrahydrofuran and water (100 ml), and then 5% aq. sol. of sodium bicarbonate (15 ml) was added. After 3 hours, reaction mixture was

-23-

diluted with dichloromethane. The organic layer was washed with water and dried over anhydrous sodium sulfate. The crude reaction mixture was chromatographed on the silicagel column (14 g) in toluene/acetone 95/5 to 5 8/2 solvent system to give 115.8 mg (69.8%) of pure compound 12.

Finally, the synthesis of 7-O-(3-O-Benzyl-2,6-dideoxy- α -Llyxo-hexopyranosyl)adriamycinone (WP 546) was 10 completed using the following steps. To the solution of compound 12 (75.5 mg, 0.10 mmol) in tetrahydrofuran (1.5 ml) solution A (tetrahydrofuran (6 ml), dichloromethane (3 ml), pyridine (150 μ l), tetrabutylammonium fluoride (1.0 M sol. in tetrahydrofuran, 150 μ l) (7.6 ml) was 15 added. After 25 min. the reaction mixture was diluted with dichloromethane, washed with water and dried over anhydrous sodium sulfate. Crude reaction mixture was chromatographed on the silicagel column in dichloromethane/diethyl ether/methanol 90/10/2 solvent 20 system to give 24.0 mg (37.8%) of pure WP 546. WP 546 was precipitated from acetone/diethyl ether/hexane and tetrahydrofuran/hexane.

EXAMPLE II

Activity of WP 549 and WP 546

Cytotoxicity of WP 546 and WP 549 Against DOX-sensitive and DOX-Resistant Cells

30 An MTT assay was performed to determine the cytotoxicity of DOX, WP 546, and WP 549 to KB 3-1 (DOX-sensitive) and KB V1 (DOX resistant) cells. The assay was performed as follows:

35 Doxorubicin was obtained from the Hospital Pharmacy (Adriamycin, Adria Laboratories, Columbus, OH). KB 3-1 human carcinoma and KB V1 were obtained from Dr. Michael

-24-

M. Gottesman at the National Cancer Institute. KB VI cells have the MDR phenotype and express glycoprotein P-170 in their membrane (Akiyama et al., *Somat. Cell. Mol. Genet.*, 11:117, 1985; Shen et al., *J. Biol. Chem.*, 261:7762, 1986.). KB 3-1 and KB Vl, cells were grown in monolayers in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. For KB Vl cells, vinblastine was added to the culture medium (final concentration 0.5 μ g/ml).

10

In vitro drug cytotoxicites against KB 3-1 and KB Vl cells were assessed by using the MTT reduction assay, as previously reported (Green et al., *J. Immunol. Methods.*, 70:257, 1984). The MTT dye was obtained from Sigma Chemical Company, St. Louis, MO. Cells were plated in 96-well microassay culture plates (10^4 cells/well) and grown for 24 h at 37°C in a 5% CO₂ incubator. Drugs were then added to the wells to achieve a final drug concentration ranging from 0.1 to 50 μ g/ml (eight wells were used for each different concentration). The same volume of 0.9% NaCl solution in water with 1% DMSO was added to control wells. Wells containing culture medium alone without cells were used as blanks. The plates were incubated at 37°C in a 5% CO₂ incubator for 1 h (KB cells). When incubation was complete, 15 μ l of stock solution of MTT dye in 0.9% NaCl solution in water was added to each well to achieve a final dye concentration of 0.5 mg/ml. The plate was incubated at 37°C in a 5% CO₂ incubator for 4 h. Subsequently, 100 μ l of medium was removed from each well from the upper]K<id,KD layer, and 100 μ l of DMSO was added to solubilize the MTT formazan. Complete solubilization was achieved by placing the plate in a mechanical shaker for 30 minutes at room temperature. The optical density of each well was then measured with a microplate spectrophotometer at a wavelength of 600 nm. The percent cell viability was calculated by the following equation:

-25-

$$\% \text{ Cell viability} = \frac{\text{Mean optical density of treated wells}}{\text{Mean optical density of control wells}} \times 100$$

5 The percent cell viability values obtained were plotted against the drug concentrations used, and the ID₅₀ was calculated from the curve. Experiments were repeated at least three time.

10 Table 1 shows the results of this study.

TABLE 1. CYTOTOXICITY OF WP 546 AND WP 549 AGAINST KB AND KBV1 CELL LINES

DRUG	ID ₅₀ ($\mu\text{g}/\text{ml}$)		RI
	KB (S)	KBV1 (R)	
Doxorubicin (DOX)	1.1	64.0	58.2
WP 546	4.6	4.1	0.9
WP 549	8.9	4.7	0.5

15 As the data in Table 1 indicate, analogs WP 546 and WP 549 were unexpectedly more cytotoxic against MDR cells than against parent cells. (ID₅₀ 4.1 and 4.7 $\mu\text{g}/\text{ml}$ for KB V1 versus 4.6 and 8.9 $\mu\text{g}/\text{ml}$ for both in KB 3.1), while the ID₅₀ of doxorubicin against the MDR cells was reached at a concentration of 64 $\mu\text{g}/\text{ml}$. In accordance with these results, the calculated resistance indices (RI = ID₅₀ KB V1/ID₅₀ KB 3-1) for WP 546 and WP 549 were surprisingly low: 0.9 and 0.5 respectively, whereas the RI for DOX was 58.2.

20 Based on these results, it is to be concluded that WP 546 and WP 549 have the ability to kill DOX-resistant and vinblastine resistant cells.

-26-

**Cytotoxicity of WP 546 and WP 549
Against AD 198 Resistant Cells**

An MTT assay to determine the cytotoxicity of WP 546
5 and WP 549 to AD 198-resistant {P 388 (R)} and AD 198-
sensitive {P388 (S)} cells was performed in a manner
similar to that described above.

Table 2 shows the results of this study:
10

**TABLE 2. CYTOTOXICITY OF WP 546 AND WP 549 AGAINST P388
(S) AND P388 (R) CELL LINES**

15 DRUG	ID ₅₀ (μ M \pm S.E.)		RI
	P388 (S)	P388 (R)	
WP 546	0.92 \pm 0.36	0.69 \pm 0.23	0.8
WP 549	1.41 \pm 0.23	0.73 \pm 0.08	0.5

20 WP 546 but especially WP 549 showed surprisingly low
RIs. The values of 0.8 and 0.5, respectively, indicate
that these analogs are more cytotoxic towards cells
selected for the resistance than that of a wild type.
These findings have implications that will be further
25 studied in the hope of discovering the mechanism whereby
WP 549 is able to overcome this resistance.

These data indicate that such analogs can be useful
agents in the treatment of tumors expressing resistance
30 to clinically useful anti-cancer agents, as well as to
agents useful in preventing preclinical development of
cancer.

-27-

**Broad Cytotoxicity of WP 546 and WP 549
Against Many Types of Drug Resistances**

An assay was run which showed that WP 546 and WP 549 had surprisingly broad cytotoxicity against: murine J774.2 cells resistant to DOX, 15-fold AD 198 resistant J7/A300 cells, and J7/40V selected for 120-fold resistance to vinblastine. This data is presented in Table 3.

10

**TABLE 3. CYTOTOXICITY OF WP 546 AND WP 549 AGAINST
J774.2, J7/A300, AND J7/40V CELL LINES**

15	DRUG	ID ₅₀ (μ M)			RI	
		J774.2	J7/A300	J7/40V	J7/A300	J7/40V
	Doxorubicin (DOX)	0.024	0.586	0.755	24	31
	AD 198	0.049	0.748	0.663	15	14
20	WP 546	1.10	2.43	2.35	2.2	2.2
	WP 549	1.43	2.77	3.15	1.9	2.3

In light of their surprisingly broad cytotoxicity, WP 546 and WP 549 may be particularly useful for the treatment of human neoplasms that are naturally resistant to anthracyclines and express P-glycoprotein, such as colon carcinoma, or that have become refractory to anthracycline therapy as a result of acquiring the multidrug-resistance phenotype after prolonged therapy with anthracyclines, vinca alkaloids, or other natural anticancer agents. The unexpected cytotoxic activity of WP 546 and WP 549 against cell lines that are resistant to AD 198 is an important finding since resistance to these cells is not associated with a reduced drug accumulation, thus indicating that WP 546 and WP 549 can overcome resistance to anthracyclines mediated by mechanisms not involving the cell membrane. Therefore,

-28-

it would appear that WP 546 and WP 549 can overcome anthracycline resistance mediated by different types of mechanisms.

5

EXAMPLE III

In Vivo Studies of WP 546 and WP 549

WP 546 and WP 549 will be tested *in vivo* for antitumor activity against murine leukemia L1210, P388, 10 and P388 resistant to doxorubicin. In conjunction with these studies, the acute and subacute toxicity will be studied in mice (LD10, LD50, LD90). In a more advanced phase of testing, the antitumor activity of WP 546 and WP 549 against human xenografts will be assessed and 15 cardiotoxicity studies performed will be done in a rat or rabbit model.

EXAMPLE IV

Treatment of Tumors with WP 546 and WP 549

20

It is anticipated that treatment with WP 546 and/or WP 549 will be along the lines of the treatment regimes of other anthracyclines and their derivatives. For example, standard treatment with doxorubicin is described 25 in *Remingtons Pharmaceutical Sciences* as follows.

Doxorubicin is administered intravenously to adults at 60 to 75 mg/m² at 21-day intervals or 25 to 30 mg/m² on each of 2 or 3 successive days repeated at 3- or 4- week 30 intervals or 20 mg/m² once a week. The lowest dose should be used in elderly patients, when there is prior bone-marrow depression caused by prior chemotherapy or neoplastic marrow invasion, or when the drug is combined with other myelopoietic suppressant drugs. The dose 35 should be reduced by 50% if the serum bilirubin lies between 1.2 and 3 mg/dL and by 75% if above 3 mg/dL. The lifetime total dose should not exceed 550 mg/m² in

-29-

patients with normal heart function and 400 mg/m² on each of 3 consecutive days, repeated every 4 weeks.

Prescribing limits are as with adults. It has been reported that a 96-hr continuous infusion is as effective
5 as and much less toxic than the same dose given by bolus injections.

Of course, modifications of the treatment regimes due to the unique nature of WP 546 and WP 549 are
10 possible and well within the ability of one skilled in the art.

- 30 -


CLAIMS

1. A compound having the formula:

5

10

15



wherein

20 R^1 is a hydrogen, hydroxyl, alkyl, arylalkyl or alkyl
in ester linkage group;

R^2 is a hydrogen or CH_2-Ar , where Ar is further
defined as being an aryl group;

25 R^3 is a hydrogen or OCH_3 group;

R^4 and R^5 are either hydrogen or hydroxyl groups; and

X is either an alkyl or fluoro-alkyl group.

30

2. The compound of claim 1, wherein Ar is a phenyl
ring.

35

3. The compound of claim 1, wherein R^1 is a hydroxyl
group.

-31-

4. The compound of claim 3, wherein the R¹ hydroxyl group is acylated.

5

5. The compound of claim 4, wherein the acyl group is valerate.

10

6. The compound of claim 1, wherein X is a methyl group.

15

7. The compound of claim 1, wherein X is a fluoro-methyl group.

20

8. The compound of claim 7, wherein R² is hydrogen.

25

9. The compound of claim 1, wherein X is a methyl group and Ar is a phenyl group.

25

10. The compound of claim 9, wherein R¹ is a hydroxyl group.

30

11. The compound of claim 10, wherein R¹ is an acylated hydroxyl group.

35

12. The compound of claim 11, wherein the acyl group is valerate.

-32-

13. A method of synthesizing a compound having the formula of claim 1 comprising adding electrophilically, 3-O-benzyl-L-fucal in which a hydroxyl group at C-4 is blocked with a halosubstituted acyl group, to an
5 anthracyclinone.

14. The method of claim 13, wherein the halosubstituted acyl group is trifluoroacetate.

10

15. The method of claim 14, wherein the synthesized compound is further defined as having a free hydroxyl group at R¹ and a methyl group at X and the synthesis further defined as comprising the steps of:

15

adding electrophilically, 3-O-benzyl-L-fucal in which a hydroxyl group at C-4 is blocked with trifluoroacetate, to 14-O-(t-butyl-dimethylsilyl)-adriamycinone to obtain 7-

20

O-(3-O-benzyl-2,6-dideoxy-4-trifluoroacetyl- α -L-lyxohexopyranosyl)-14-O-(t-butyl-dimethylsilyl)adriamycinone;

25

removing the trifluoroacetate to obtain 7-O-(3-O-benzyl-2,6-dideoxy- α -L-lyxo-hexopyranosyl)-14-O-(t-butyl-dimethylsilyl)adriamycinone;

30

completing the synthesis to obtain 7-O-(3-O-benzyl-2,6-dideoxy- α -L-lyxo-hexopyranosyl)adriamycinone.

35 16. The method of claim 14, wherein the synthesized compound is further defined as having valerate at R¹ and a

-33-

methyl group at X and the synthesis further defined as comprising the steps of:

starting with daunomycinone;

5

preparing 14-bromodaunomycinone from the
duanomycinone;

10

preparing 14-O-valeroyladriamycinone from
the 14-bromoduanomycinone;

15

adding electrophilically, 3-O-benzyl-L-
fucal in which a hydroxyl group at C-
4 is blocked with trifluoroacetate,
to the 14-O-valeroyl-adriamycinone
to obtain 7-O-benzyl-2,6-dideoxy-4-
trifluoro-acetyl- α -L-lyxo-
hexopyranosyl)-14-O-
valeroyladriamycinone;

20

removing the trifluoroacetate to obtain 7-
O-(3-O-benzyl-2,6-dideoxy- α -L-lyxo-
hexopyranosyl)-14-O--
valeroyladriamycinone;.

25

17. A method of treating a patient with cancer
comprising the step of administering to the patient a
therapeutically effective amount of the compound of claim

30

1.

35

18. A modified anthracycline having an O-CH₂-Ar group
attached to C-3 of a sugar moiety, where Ar is further
defined as being an aromatic ring.

-34-

19. The modified anthracycline of claim 18, wherein Ar is a phenyl ring.

5 20. An anthracycline preparable by adding electrophilically, 3-O-benzyl-L-fucal in which a hydroxyl group at C-4 is blocked with a halosubstituted acyl group, to an anthracyclinone.

10 21. The method of claim 13, wherein the halosubstituted acyl group is trifluoroacetate.

1/3

Figure 1






Figure 2

Figure 3

INTERNATIONAL SEARCH REPORT

I. National application No. PCT/US94/02619

A. CLASSIFICATION OF SUBJECT MATTER

IPC(S) :A61K 31/70; C07H 1/00, 15/24
US CL :514/34; 536/6.4, 18.5, 18.6

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/34; 536/6.4, 18.5, 18.6

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 4,201,773 (HORTON ET AL) 06 May 1980, col. 1, lines 6-58.	1-21
X	US, A, 4,870,058 (HORTON ET AL) 26 September 1989, col. 2, lines 1-46.	1-21

Further documents are listed in the continuation of Box C. See patent family annex.

Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be part of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

25 May 1994

Date of mailing of the international search report

10 JUN 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Faxsimile No. (703) 305-3230

Authorized officer

ELLI PESELEV

Telephone No. (703) 308-0196